Stockreport

TD Cowen Initiates Orchestra BioMed (OBIO), Cites High-Margin Potential in Lead Cardiovascular Programs [Yahoo! Finance]

Orchestra BioMed Holdings, Inc. - Ordinary Shares  (OBIO) 
PDF analyst Joshua Jennings initiated coverage of Orchestra BioMed with a Buy rating and $15 price target. TD Cowen believes that Orchestra BioMed is at the leading edge of [Read more]